Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptide-based immunization therapy for treatment of atherosclerosis

a technology of atherosclerosis and immunization therapy, which is applied in the field of new peptides, can solve the problems that the immunization treatment of atherosclerosis using intact oxidised ldl could have a detrimental effect, and not always the case, and achieve the effect of protecting atherosclerosis and strong cellular immune respons

Inactive Publication Date: 2008-03-20
CARDIOVAX
View PDF3 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about a new technique for diagnosing and treating cardiovascular disease using a peptide called apoB. This peptide is attached to polymer wells and when a blood sample is added, antibodies that bind to the peptide are determined using an immunological method. The technique is different from previous methods because it is based on the discovery of immune reactions against the peptide sequence. The invention also includes a method for immunizing against atherosclerosis by using a combination of peptides that have been found to elicit a protective immune response. The use of antibodies directed to structures present in particles of oxidized LDL is not described in previous patents. The invention is based on the principle that oxidation of lipoproteins, mainly LDL, in the arterial wall is an important factor in the development of atherosclerosis and that products generated during oxidation of LDL are toxic to vascular cells, cause inflammation and initiate plaque formation."

Problems solved by technology

Previous results have (PCT / SE02 / 00679, above), however, surprisingly shown that this is not always the case.
Further, they show that immunisation using intact oxidised LDL could have a detrimental effect if the particles used contain a large amount of structures that give rise to atherogenic immuno reactions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide-based immunization therapy for treatment of atherosclerosis
  • Peptide-based immunization therapy for treatment of atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] It has thereby been determined that the following peptide, when derivatized with MDA fulfills the criteria required to initiate a cellular immune response. This peptide is

NH2-PTVMDFRKFSRNYQLYKSVSLPS-COOHSEQ. ID. NO. 1

or an active part of this peptide.

[0027] The present peptide, SEQ. ID. NO 1, is based on amino acids 625-647 of the amino acid sequence of the human apoB100 protein.

[0028] When a peptide synthesized to contain this amino acid sequence is conjugated with MDA and injected into atherosclerosis-prone mice together with a suitable adjuvant, it reduces the development of atherosclerosis in the animals.

[0029] The present invention thus relates to a fragment of apoB intended for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases and having immunological prophylactic or therapeutic properties against ischemic cardiovascular diseases, and / or diagnosing the presence or absence of antibodies related to increased...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
widthaaaaaaaaaa
concentrationaaaaaaaaaa
external radioactivity analysisaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic cardiovascular diseases including stroke, using said peptide in an assay, pharmaceutical compositions comprising the peptide. The invention further encompasses a particular peptide sequence aggravating disease, which sequence then can be used for diagnostic assays.

Description

PRIORITY INFORMATION [0001] The present invention is a divisional of U.S. patent application Ser. No. 11 / 373,682 filed on Mar. 10, 2006 which is a continuation of PCT Application No. PCT / SE2004 / 001239, filed on Aug. 30, 2004, which claims priority to Swedish Application No. 0302422-1, filed on Sep. 11, 2003.BACKGROUND OF THE INVENTION [0002] 1.Field of the Invention [0003] The present invention relates to a new peptide, in particular a peptide to be used for immunization therapy for treatment of atherosclerosis, and for development of peptide based immunochemical assay for the determination of immune response against oxidized low density lipoprotein and the diagnosis of the presence or absence of atherosclerosis. [0004] In particular the invention includes: [0005] 1) The use of the peptide of the invention alone, native or MDA-modified, preferably together with a suitable carrier and adjuvant as an immunotherapy or “anti-atherosclerosis “vaccine” for prevention and treatment of isch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/48C12Q1/02G01N33/68A61K39/00C07K14/775C07K16/18
CPCA61K39/0012C07K14/775G01N2800/324G01N33/6893C07K16/18A61P9/00
Inventor HANSSON, GORAN K.
Owner CARDIOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com